Expert perspectives on novel management of HER2+ metastatic breast cancer in the context of recent clinical trials and FDA approvals.
EP. 1: HER2+ mBC: Overview of Treatment Options and Sequencing
EP. 2: DESTINY-Breast03: T-DXd in HER2+ Metastatic Breast Cancer
Expert perspectives on the DESTINY-Breast03 trial, which compared T-DXd to T-DM1 in the setting of relapsed/refractory HER2+ metastatic breast cancer.
EP. 3: HER2+ mBC: Safety Outcomes From the DESTINY-Breast03 Trial
Insight on the safety events observed in the DESTINY-Breast03 trial and how this translates to real-world adverse event management in HER2+ metastatic breast cancer.
EP. 4: Impact of DESTINY-Breast03 on Real-World Management of HER2+ mBC
Focusing on real-world treatment selection, Cynthia Lynch, MD, considers how the DESTINY-Breast03 trial impacted her practice and broader treatment guidelines.
EP. 5: Recently Approved Regimens for HER2+ Metastatic Breast Cancer
Data from the HER2CLIMB, NALA, and SOPHIA trials that led to the FDA approval of respective agents in the setting of HER2+ metastatic breast cancer.
EP. 6: HER2+ mBC: Sequencing Novel Treatment Regimens
In the context of recently approved novel regimens, expert Cynthia Lynch, MD, revisits the optimal sequencing of therapy for patients with HER2+ metastatic breast cancer.
EP. 7: Treating Brain Metastases and the future of HER2+ mBC
Closing out her discussion on HER2+ metastatic breast cancer, Cynthia Lynch, MD, shares her excitement for treatment strategies in the setting of brain metastases.
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma